MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.35 USD
-0.04 (-1.27%)
Updated Sep 20, 2024 09:38 AM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 161 - 180 ( 364 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Re-Assessing Pipeline Valuations for 2019, SOPHIA Topline up Next
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
Margetuximab + Keytruda is Potentially Safer With Activity in- Line With Chemo-Based SOC in Second-Line Gastric Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MGD009 Program Hiccup Puts More Onus on SOPHIA Phase 3 Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
ASH 2018: Key Presentations Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Flotetuzumab Updates From ASH; Compelling Responses in Refractory AML in Need of Further Prospective Confirmation
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Going East Where the Sun Rises; Makes Perfect Sense Given Margetuximab''s Profile in Gastric Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
3Q18 Corporate Update; Enthusiasm Around the Upcoming Enoblituzumab Presentation at the SITC Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
SOPHIA Results Likely Soon in 2019, Pipeline Progresses
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: MacroGenics, Inc.
Industry: Medical - Products
UPDATED: ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
CORRECTED: ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
ASH 2018 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Expecting Insights Into the Path Forward for Enoblituzumab at the SITC Meeting on November 7 to 11, 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Biotechnology - ESMO 2018 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Pre-ASH Catalyst Calendar For Stocks Under Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D